CN1205221C - 修饰的凝血因子ⅷ - Google Patents

修饰的凝血因子ⅷ Download PDF

Info

Publication number
CN1205221C
CN1205221C CNB018191495A CN01819149A CN1205221C CN 1205221 C CN1205221 C CN 1205221C CN B018191495 A CNB018191495 A CN B018191495A CN 01819149 A CN01819149 A CN 01819149A CN 1205221 C CN1205221 C CN 1205221C
Authority
CN
China
Prior art keywords
factor viii
coagulation factor
blood coagulation
leu
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018191495A
Other languages
English (en)
Chinese (zh)
Other versions
CN1474830A (zh
Inventor
J·S·洛拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Publication of CN1474830A publication Critical patent/CN1474830A/zh
Application granted granted Critical
Publication of CN1205221C publication Critical patent/CN1205221C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/10—Factor VIII, AHF; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CNB018191495A 2000-09-19 2001-09-19 修饰的凝血因子ⅷ Expired - Fee Related CN1205221C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23404700P 2000-09-19 2000-09-19
US60/234,047 2000-09-19
US23646000P 2000-09-29 2000-09-29
US60/236,460 2000-09-29

Publications (2)

Publication Number Publication Date
CN1474830A CN1474830A (zh) 2004-02-11
CN1205221C true CN1205221C (zh) 2005-06-08

Family

ID=26927505

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018191495A Expired - Fee Related CN1205221C (zh) 2000-09-19 2001-09-19 修饰的凝血因子ⅷ

Country Status (12)

Country Link
US (1) US6770744B2 (enExample)
EP (1) EP1319016A4 (enExample)
JP (1) JP2004525608A (enExample)
KR (1) KR100638184B1 (enExample)
CN (1) CN1205221C (enExample)
AU (1) AU2001292861A1 (enExample)
CA (1) CA2422902A1 (enExample)
HU (1) HUP0301179A3 (enExample)
MX (1) MXPA03002256A (enExample)
PL (1) PL206105B1 (enExample)
RU (1) RU2003107100A (enExample)
WO (1) WO2002024723A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
MXPA04005079A (es) * 2001-11-30 2004-08-19 Univ Emory Variantes del dominio c2 del factor viii.
US7485291B2 (en) 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
US7709224B2 (en) 2003-06-03 2010-05-04 Biosante Pharmaceuticals, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US20050123997A1 (en) * 2003-10-30 2005-06-09 Lollar John S. Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes
US7855274B2 (en) * 2003-12-03 2010-12-21 University Of Rochester Recombinant factor VIII having increased specific activity
EP1750733B1 (en) * 2004-05-03 2013-12-11 Emory University METHOD OF ADMINISTERING PORCINE B-DOMAINLESS fVIII
SI1824988T1 (sl) 2004-11-12 2017-11-30 Bayer Healthcare Llc Usmerjena modifikacija FVIII
WO2006063031A2 (en) 2004-12-06 2006-06-15 Haplomics Allelic variants of human factor viii
FR2913020B1 (fr) * 2007-02-23 2012-11-23 Biomethodes Nouveaux facteurs viii pour le traitement des hemophiles de type a
CA2703948A1 (en) * 2007-11-01 2009-05-07 University Of Rochester Recombinant factor viii having increased stability
CN104059155A (zh) * 2008-05-16 2014-09-24 拜耳医药保健有限公司 靶向性凝固因子及其使用方法
BR112012004094A2 (pt) 2009-08-24 2016-03-08 Amunix Operating Inc composições de fator vii de coagulação e métodos para fazer e usar as mesmas
EP2498804A4 (en) * 2009-11-13 2013-05-08 Puget Sound Blood Ct FACTOR VIII B CELL EPITOPARIANTS WITH REDUCED IMMUNOGENITY
US20110177107A1 (en) * 2010-01-14 2011-07-21 Haplomics, Inc. Predicting and reducing alloimmunogenicity of protein therapeutics
US9150637B2 (en) 2010-11-05 2015-10-06 Baxalta Inc. Variant of antihemophilic factor VIII having increased specific activity
HRP20221531T1 (hr) 2012-02-15 2023-02-17 Bioverativ Therapeutics Inc. Pripravci faktora viii i postupci dobivanja i korištenja istih
LT2822577T (lt) 2012-02-15 2019-03-25 Bioverativ Therapeutics Inc. Rekombinantiniai faktoriaus viii baltymai
US10272163B2 (en) 2012-12-07 2019-04-30 The Regents Of The University Of California Factor VIII mutation repair and tolerance induction
US10093901B2 (en) 2013-05-10 2018-10-09 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Use of specific regulatory T-cells to induce immune tolerance
WO2014209942A1 (en) 2013-06-24 2014-12-31 Weidong Xiao Mutant factor viii compositions and methods
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
US10058624B2 (en) * 2015-04-16 2018-08-28 Emory University Recombinant promoters and vectors for protein expression in liver and use thereof
MX2018001497A (es) 2015-08-03 2018-05-15 Bioverativ Therapeutics Inc Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
PE20231949A1 (es) 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
WO2018102743A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
US20210093735A1 (en) * 2018-04-26 2021-04-01 The University Of North Carolina At Chapel Hill Methods and compositions for treatment of hemophilia
RS66972B1 (sr) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc Metode lečenja hemofilije a
US11795207B2 (en) 2021-03-30 2023-10-24 AAVnerGene Inc. Modified plasma clotting factor VIII and method of use thereof
CN117157316A (zh) 2021-03-30 2023-12-01 艾诺健基因治疗股份有限公司 修饰的血浆凝血因子viii及其使用方法
CN113970279B (zh) * 2021-10-26 2023-07-07 珠海城市职业技术学院 数字式螺旋测微仪
CN114196677A (zh) * 2021-12-30 2022-03-18 广西医科大学第一附属医院 一种高活性的凝血因子Ⅷ或Ⅷa多肽变体Gly710Ala

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663060A (en) * 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US6180371B1 (en) 1996-06-26 2001-01-30 Emory University Modified factor VIII
US5888974A (en) * 1992-04-07 1999-03-30 Emory University Hybrid human/animal factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
CA2225189C (en) * 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
AU6770200A (en) * 1999-08-13 2001-03-13 Fred Hutchinson Cancer Research Center Crystal of a truncated protein construct containing a coagulation factor viii c2domain in the presence or absence of a bound ligand and methods of use thereof
EP1460131A3 (en) * 2000-03-22 2005-06-01 Octagene GmbH Production of recombinant blood clotting factors in human cell lines

Also Published As

Publication number Publication date
JP2004525608A (ja) 2004-08-26
CA2422902A1 (en) 2002-03-28
RU2003107100A (ru) 2004-08-27
AU2001292861A1 (en) 2002-04-02
PL366199A1 (en) 2005-01-24
EP1319016A4 (en) 2006-05-10
US20020182670A1 (en) 2002-12-05
HUP0301179A2 (hu) 2003-10-28
KR100638184B1 (ko) 2006-10-26
KR20030033074A (ko) 2003-04-26
US6770744B2 (en) 2004-08-03
HUP0301179A3 (en) 2006-11-28
MXPA03002256A (es) 2003-09-10
WO2002024723A9 (en) 2003-04-03
WO2002024723A1 (en) 2002-03-28
EP1319016A1 (en) 2003-06-18
PL206105B1 (pl) 2010-07-30
CN1474830A (zh) 2004-02-11

Similar Documents

Publication Publication Date Title
CN1205221C (zh) 修饰的凝血因子ⅷ
CN1191360C (zh) 修饰的凝血因子ⅷ
CN1224627C (zh) 修饰的凝血因子ⅷ
CN1033760C (zh) 产生具有第八因子活性的第八因子缺失突变体的方法
EP0910628B1 (en) Inactivation resistant factor viii
AU2007269233B2 (en) Method of producing Factor VIII proteins by recombinant methods
CN1745100A (zh) 因子ⅷ多肽
US20130072434A1 (en) Inactivation resistant factor viii
WO1997040145A9 (en) Inactivation resistant factor viii
US20040092442A1 (en) Inactivation resistant factor VIII
CN1630666A (zh) 因子ⅷc2结构域变体
WO2012170289A1 (en) Method of producing factor viii proteins by recombinant methods
CN1646564A (zh) 修饰的因子ⅷ
US20140357565A1 (en) Method of producing factor viii proteins by recombinant methods
CN1179976C (zh) 产生凝血因子ⅷ的生产方法和宿主细胞
US20090203077A1 (en) Method of producing factor viii proteins by recombinant methods
US20030148953A1 (en) Inactivation resistant factor VIII
HK1178545A (en) Method of producing factor viii proteins by recombinant methods
CN1040203A (zh) 抗聚集肽

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee